Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2022）

引用 4|浏览21

暂无评分

摘要

SRT plus ENZA monotherapy for 6 months in men with PSA-recurrent high-risk prostate cancer after RP is safe and delays PSA progression relative to SRT alone. The impact of ENZA on distant metastasis or survival is unknown at this time.

查看译文

关键词

radical prostatectomy,salvage radiation therapy,enzalutamide,high-risk,prostate-specific,salv-enza

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要